Diagnostic Value of Cryptococcal Glucuronoxylomannan Antigen Testing of Bronchoalveolar Lavage Fluid for Pulmonary Cryptococcosis in Immunocompetent Patients: A Clinical Study
Therapeutic Advances in Pulmonary and Critical Care Medicine · 2025
DOI: 10.1177/29768675251363301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Pulmonary and Critical Care Medicine, 2025. Verfasst von Shuangxia Dong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory, The Wenzhou Central Hospital and Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science and Technology Plan Project of Wenzhou Municipality.
Abstract (Originalsprache)
Background [No revision is required.]Pulmonary cryptococcosis (PC) is common in immunocompetent patients, and its early diagnosis is challenging. Multiple studies have addressed the detection of cryptococcal glucuronoxylomannan (GXM) antigen in serum, but few have investigated its detection in bronchoalveolar lavage fluid (BALF).
Objectives
To evaluate the diagnostic value of the Cryptococcus GXM antigen test in BALF for PC in immunocompetent patients.
Design
We collect the clinical data of 138 patients from October 2018 to March 2023 and divide them into a PC group (n = 48) and a non-PC group (n = 90). Perform serum and BALF GXM antigen test on all cases that meet the inclusion criteria.
Methods
To analyze and compare the clinical characteristics of the PC group and non-PC group. We calculate the positive detection rate (PDR) and negative predictive value of BALF and serum GXM antigen tests, as well as their combination, for the PC group.
Results
Most patients in the PC group are male (59.6%), with an average age of 49.4 years. Most of the patients have no underlying disease (51.9%). Diabetes and hypertension are the most common comorbidities. Most patients (53.8%) are asymptomatic. Cough and sputum are the most frequent clinical symptoms, followed by fever and chest distress. Nodules and exudative consolidation are the most common imaging findings, and the culture positivity rate is 25%. Forty patients are positive according to the BALF GXM test, for a positivity rate of 83.3% and a negative predictive value of 91.8%. Moreover, 39 patients are positive according to the serum GXM test, for a positivity rate of 81.3% and a negative predictive value of 90.9%. The positivity rate for serum plus BALF is 95.8%. There is no significant difference (P > 0.05) in diagnostic value between BALF and serum GXM tests for PC. GXM positivity rates differ significantly among paired BALF, serum, and BALF plus serum groups (P < 0.05).
Conclusion
The BALF GXM test is useful for the early diagnosis of PC in immunocompetent patients. Simultaneous BALF and serum GXM testing would increase the rate of early PC diagnosis in immunocompetent patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory, The Wenzhou Central Hospital and Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, China.
ORCID-Profile: Shuangxia Dong
Förderung
- Science and Technology Plan Project of Wenzhou Municipality
Zitieren
APA
Dong, S., Dai, X., Pang, L., & Huang, Y. (2025). Diagnostic Value of Cryptococcal Glucuronoxylomannan Antigen Testing of Bronchoalveolar Lavage Fluid for Pulmonary Cryptococcosis in Immunocompetent Patients: A Clinical Study. Therapeutic Advances in Pulmonary and Critical Care Medicine. https://doi.org/10.1177/29768675251363301
Vancouver
Dong S, Dai X, Pang L, Huang Y. Diagnostic Value of Cryptococcal Glucuronoxylomannan Antigen Testing of Bronchoalveolar Lavage Fluid for Pulmonary Cryptococcosis in Immunocompetent Patients: A Clinical Study. Therapeutic Advances in Pulmonary and Critical Care Medicine. 2025. doi:10.1177/29768675251363301
BibTeX
@article{Dong2025,
author = {Dong, Shuangxia and Dai, Xinjian and Pang, Linyan and Huang, Yang},
title = {Diagnostic Value of Cryptococcal Glucuronoxylomannan Antigen Testing of Bronchoalveolar Lavage Fluid for Pulmonary Cryptococcosis in Immunocompetent Patients: A Clinical Study},
journal = {Therapeutic Advances in Pulmonary and Critical Care Medicine},
year = {2025},
doi = {10.1177/29768675251363301}
}
EUVIMED